Target disease
Chronic Hepatitis B
Molecular type
Nucleoside monophosphate prodrug
Mode of action
RT inhibitor
Development stage
GLP preclinical studies
for US FDA IND enabling
Best-in-class RT inhibitor
Superior to ETV/TDF/TAF

Hepatitis B

  • In 2019, WHO estimates that 296 million people were living with chronic hepatitis B (CHB) infection with 1.5 million new infections each year.
  • In 2019, hepatitis B resulted in an estimated 820,000 deaths, mostly from cirrhosis and hepatocellular carcinoma (HCC).
  • Hepatitis B can be prevented by vaccines, which are safe, available and effective, but still lots of patients are suffering from CHB.
  • Current treatment option for CHB patients are five US FDA approved antivirals and two IFNs , but the cure rate is less than 5%.
Hepatitis B